CN Mobile Logo

Search form


Leah Lawrence

A study found that normal-weight women should be evaluated for metabolic health to reduce their risk for colorectal cancer.

A study showed that testing pediatric brain tumors for genetic abnormalities is feasible and could play a role in guiding patients’ treatment.

Young and middle-aged patients diagnosed with colon cancer were more likely to receive postoperative chemotherapy compared with their older-age counterparts, according to the results from a recent cohort study.

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

The FDA recently approved the oral BTK inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.

Use of communication coaching that included a question prompt list—or structured lists of questions given to patients prior to consultations—helped patients with advanced cancer and their caregivers to bring up topics of concern during oncology office visits.

Using immunohistochemistry to measure the expression of certain target enzymes—cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas.

The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer.

The immune checkpoint inhibitor nivolumab showed durable responses and disease control in a group of heavily pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer.

Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.


Subscribe to RSS - Leah Lawrence

By clicking Accept, you agree to become a member of the UBM Medica Community.